Loading organizations...
§ Private Profile · Ann Arbor, MI, USA
Biopharmaceutical company developing intranasal vaccines using NanoVax technology for respiratory and sexually transmitted diseases.
BlueWillow Biologics is an Ann Arbor, Michigan-based biopharmaceutical company that develops intranasal vaccines for respiratory and sexually transmitted diseases using its proprietary NanoVax technology platform. The clinical-stage enterprise utilizes a patented oil-in-water nanoemulsion adjuvant, which is delivered via nasal spray to elicit both mucosal and systemic immunity against targeted pathogens. Operating as a privately held corporate entity, the firm secured $10 million in Series A financing during May 2018 to further advance its primary research and development pipeline. This specific venture capital funding round was financially supported by institutional investors including North Coast Technology Investors, Line Moon Ventures, and University of Michigan MINTS. The organization also supplements its private equity backing with direct federal grant support from the National Institutes of Health. BlueWillow Biologics was originally founded in 2000 by James Baker.
BlueWillow Biologics has raised $21.0M across 2 funding rounds.
BlueWillow Biologics has raised $21.0M in total across 2 funding rounds.
BlueWillow Biologics has raised $21.0M across 2 funding rounds. Most recently, it raised $10.0M Series A in May 2018.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| May 7, 2018 | $10M Series A | Line Moon Ventures, North Coast Technology Investors, University OF Michigan | — | Announced |
| Nov 28, 2012 | $11M Series C | — | — | Announced |
BlueWillow Biologics has raised $21.0M in total across 2 funding rounds.
BlueWillow Biologics's investors include Line Moon Ventures, North Coast Technology Investors, University of Michigan.